skip to main content

Our Private Equity Group provides trusted counsel derived from deep industry knowledge to established as well as up-and-coming private equity firms. We represent firms of every size across the spectrum of investment strategies, and we build long-standing relationships with our clients. As active participants in the private equity industry, we are able to advise our clients on the latest innovations, as well as current market practices and trends.

PCI Pharma To Acquire LSNE

Paul, Weiss is advising PCI Pharma Services, a leading pharmaceutical and biopharmaceutical global integrated solutions provider and portfolio company of Kohlberg & Company, LLC, in its acquisition of Lyophilization Services of New England, Inc. (LSNE) from global private equity firm Permira. LSNE is a New Hampshire-based premier contract development and manufacturing organization (CDMO).

The transaction will expand PCI’s breadth of services as a global CDMO, building on PCI’s expertise in biologics packaging and specialty manufacturing. It will add five FDA-approved facilities in the U.S. and Europe, with a sixth expecting approval over the coming months, and three additional facilities under development, to PCI’s global 30-site network. Financial terms of the deal were not disclosed.

The Paul, Weiss team includes corporate partners Angelo Bonvino, Thomas de la Bastide and Tracey Zaccone and counsel Julie Martinelli and Suhan Shim; tax partner Lindsay Parks; intellectual property partner Charles Googe; litigation partner Aidan Synnott and counsel Peter Jaffe and Steven Herzog; real estate partner Peter Fisch; executive compensation counsel Meghan Fox and Reuven Falik; international trade counsel Richard Elliott; and antitrust counsel Marta Kelly.

© 2022 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy